| 2009-03 |
Discovery and development of novel furano-pyrimidine analogs as Aurora kinase inhibitors |
Abstracts of Papers - American Chemical Society. 2009 Mar;237:MEDI 221. |
 |
| 2016-04 |
Discovery and development of tylophorine derived dibenzoquinolines-33b compounds into therapeutic agents |
The FASEB Journal. 2016 Apr;30(1, Suppl.):Meeting Abstract lb56. |
 |
| 2011-07 |
Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3) |
Bioorganic and Medicinal Chemistry. 2011 Jul;19(14):4173-4182 . |
|
| 2013-11 |
Discovery and refinement of loci associated with lipid levels |
Nature Genetics. 2013 Nov;45(11):1274-1283. |
|
| 2014-08 |
Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors |
Bioorganic and Medicinal Chemistry Letters. 2014 Aug;24(15):3403-3406. |
|
| 2021-05-19 |
Discovery and synthesis of a pyrimidine-based aurora kinase inhibitor to reduce levels of MYC oncoproteins |
Journal of Medicinal Chemistry. 2021 May 19;64(11):7312-7330. |
|
| 2010-09 |
Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophe n-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist |
ChemMedChem. 2010 Sep;5(9):1439-1443. |
|
| 2013-11-13 |
Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5 -(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice |
Journal of Medicinal Chemistry. 2013 Nov 13;56(24):9920-9933. |
|
| 2015-08 |
Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 182. |
|
| 2009-07-23 |
Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice |
Journal of Medicinal Chemistry. 2009 Jul 23;52(14):4496-4510. |
|
| 2013-06 |
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3) |
Bioorganic and Medicinal Chemistry. 2013 Jun;21(11):2856-2867. |
|
| 2008-07-24 |
Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors |
Journal of Medicinal Chemistry. 2008 Jul;51(14):4351-4355. |
|
| 2022-06-02 |
Discovery of a biomarker signature that reveals a molecular mechanism underlying diabetic kidney disease via organ cross talk |
Diabetes Care. 2022 Jun 2;45(6):e102-e104. |
|
| 2019-11-27 |
Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer |
Journal of Medicinal Chemistry. 2019 Nov 27;62(22):10108-10123. |
|
| 2024-06-01 |
Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus |
Molecular Cancer Therapeutics. 2024 Jun 01;23(6):766-779. |
|
| 2021-10-09 |
Discovery of a metabolic signature predisposing high risk patients with mild cognitive impairment to converting to Alzheimer’s disease |
International Journal of Molecular Sciences. 2021 OCt 9;22(20):Article number 10903. |
|
| 2024-07-17 |
Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia |
Cell Chemical Biology. 2024 Jul 17;Article in Press. |
|
| 2006-06-15 |
Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies |
Journal of Medicinal Chemistry. 2006 Jun;49(12):3485-3495. |
|
| 2021-06-16 |
Discovery of an orally efficacious MYC inhibitor for liver cancer using a GNMT-based high-throughput screening system and structure-activity relationship analysis |
Journal of Medicinal Chemistry. 2021 Jun 16;64(13):8992-9009. |
|
| 2014-10 |
Discovery of ATR kinase inhibitors from natural products |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1637. |
|
| 2016-12 |
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Oncotarget. 2016 Dec;7(52):86239-86256. |
|
| 2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482. |
|
| 2021-10-14 |
Discovery of BPR1R024, an orally active and selective CSF1R inhibitor that exhibits antitumor and immunomodulatory activity in a murine colon tumor model |
Journal of Medicinal Chemistry. 2021 Oct 14;64(19):14477-14497. |
|
| 2019-10 |
Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer |
Annals of Oncology. 2019 Oct;30(Suppl. 5):789. |
|
| 2019-04-10 |
Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants |
Journal of Medicinal Chemistry. 2019 Apr 10;62(8):3940-3957. |
|
